QQ客服 官方微博 反馈留言

	Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib
	Ma, Di; Zhang, Yan; Xing, Puyuan; Hao, Xuezhi; Wang, Mengzhao; Wang, Yan; Shan, Li; Xin, Tao; Liang, Hongge; Du, Yang
	2019
卷号	10期号:5页码:1213-1219
关键词	Anaplastic lymphoma kinase crizotinib non-small cell lung cancer primary resistance
ISSN号	1759-7706
DOI	10.1111/1759-7714.13071
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6341778
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Ma, Di,Zhang, Yan,Xing, Puyuan,et al. Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib[J],2019,10(5):1213-1219.
APA	Ma, Di.,Zhang, Yan.,Xing, Puyuan.,Hao, Xuezhi.,Wang, Mengzhao.,...&Li, Junling.(2019).Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib.,10(5),1213-1219.
MLA	Ma, Di,et al."Clinical features and outcomes of ALK rearranged non-small cell lung cancer with primary resistance to crizotinib".10.5(2019):1213-1219.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。